Company Information
Press Room
Top-Line Industry Data
News Releases
Articles & Presentations
Press Contacts
Prescription Restraint Laws Challenged
Investor Center
Corporate Governance
Careers
Privacy Commitment

Meet Our Leadership Team
Glance at IMS Facts
Learn About Our History
Articles & Publications
Articles & Presentations

IMS works with a variety of media outlets and trade associations to share expertise on issues impacting the pharmaceutical industry. This section provides abstracts and PDFs of current published articles, as well as extracts from recent industry presentations.
 Page: 1  2  3  4  5  6  7  8  9  10   >>

Are You Patient-Centric? New Essentials That Will Transform Your Sales and Marketing Strategy

Jun 15, 2008

IMS Again Named to BusinessWeek Best-Performing U.S. Companies

Apr 1, 2008

IMS Among ‘America’s Most Admired Companies’ in Fortune Magazine’s Latest Survey
In a survey of industry peers, IMS ranked second in the “Health Care: Pharmacy and Other Services” category of this annual report card on corporate reputations.
Mar 9, 2008

In the News: IMS Predicts Dramatic Growth, Points Out Potential Perils in Emerging Markets
Murray Aitken, IMS senior VP, Healthcare Insight, told attendees at a London conference sponsored by The Economist on Feb. 27, based on IMS forecasts, emerging markets will become an increasingly important driver of global pharmaceutical growth in future years.
Mar 2, 2008

Zero-Sum Game? Breakthroughs in the War on Cancer Mean Challenges in the Marketplace
Oncology has been the fastest-growing pharmaceutical sector over the last decade, with companies announcing breakthrough after breakthrough. But that very success is breeding changes in the market. Could the combination end up creating a zero-sum game for patients?
Jan 23, 2008

Physician or Pharmacist? U.S. Weighs “Behind-the-Counter” Drug Sales
“By prescription only” and “over-the-counter” (OTC) are the traditional tiers of drug availability in the U.S. But a third tier may be coming, one that has been available in other parts of the world for some time: so-called “behind-the-counter,” or BTC.
Nov 26, 2007

Drugs Move to Behind-the-Counter
Increasingly, concerns from drug manufacturers and patients alike have called out the need for a new drug category that could open up access to the uninsured and those who can’t afford a doctor. On October 4, 2007 the FDA sent out a newsletter seeking comments on the “health benefits of drugs being available without a prescription but only after intervention by a pharmacist.” Effectively, they are considering a new drug classification dubbed ‘behind-the-counter’ (BTC), which would serve as an intermediary between prescriptions and over-the-counter (OTC) drugs.
Nov 26, 2007

Cervical Cancer – No Longer a Natural Born Killer?
In Europe, cervical cancer is the second leading cause of cancer deaths among women, with around 33,500 women diagnosed annually, and some 15,000 deaths. In the U.S., about 14,000 are diagnosed each year, leading to approximately 3,900 deaths. The human pappillomavirus, or HPV, is believed responsible for the overwhelming majority of these cancers.
Oct 11, 2007

A New Pharma Market Needs New Metrics
Emerging markets are taking an increasing share of global pharmaceutical market growth. Primary care products are giving way to those aimed at specialists. Thanks to the Internet, the informed patient is coming of age. And all of this change is taking place in an environment dominated by cost containment and cutting.
Oct 4, 2007

Forbes.com Features IMS CEO Dave Carlucci Commentary on Healthcare Solutions
Forbes.com recently tapped IMS Chairman and CEO Dave Carlucci to offer his perspectives on how best to solve the healthcare dilemma. Carlucci is just one of the commentators featured, saying that one way to assure quality, affordable healthcare is greater access to healthcare information.
Sep 17, 2007


 Page: 1  2  3  4  5  6  7  8  9  10   >>









Home | Contact | Search | Site Map | FAQ | Privacy | Websites
Copyright © 2007 IMS Health Incorporated. All rights reserved.  







Murray Aitken, senior vice president, Market Insights, discusses the importance of the emerging markets in driving pharmaceutical industry growth with Reuters
  more